title: Reduction of Blood Pressure by AT1 Receptor Decoy Peptides.
abstract: BACKGROUND
  We previously identified the binding of the chaperone protein gamma-aminobutyric acid receptor-associated protein (GABARAP) to a sequence on the carboxy-terminus of the angiotensin II AT1 receptor (AT1R) and showed that this binding enhances AT1R trafficking to the cell surface as well as angiotensin signaling.
  
  
  METHODS
  In this study, we treated sodium-depleted mice with decoy peptides consisting either of a fusion of the cell-penetrating peptide penetratin and the GABARAP/AT1R binding sequence or penetratin fused to a mutated AT1R sequence. We used telemetry to measure blood pressure.
  
  
  RESULTS
  Systolic and diastolic pressure fell during the 24 hours following decoy peptide injection but not after control peptide injection. Active cell-penetrating decoy peptide decreased 24-hour average systolic blood pressure from 129.8 ± 4.7 mmHg to 125.0 ± 6.0 mmHg (mean ± standard deviation). Diastolic blood pressure fell from 99.0 ± 7.1 mmHg to 95.0 ± 9.2 mmHg (n=5). Administration of the control peptide raised systolic blood pressure from 128.7 ± 1.3 mmHg to 131.7 ± 2.9 mmHg and diastolic pressure from 93.9 ± 4.5 mmHg to 95.9 ± 4.2 mmHg (n=5). The decreases in both systolic and diastolic blood pressure after active peptide administration were statistically significant compared to control peptide administration (P<0.05, two-tailed Wilcoxon rank-sum test).
  
  
  CONCLUSIONS
  These results indicate the physiological and potentially therapeutic relevance of inhibitors of GABARAP/AT1R binding.
authors.affiliation: Department of Cardiology.
authors.forename: Richard N
authors.initials: RN
authors.lastname: Re
authors.forename: Ben
authors.initials: B
authors.lastname: Chen
authors.forename: Jawed
authors.initials: J
authors.lastname: Alam
authors.forename: Julia L
authors.initials: JL
authors.lastname: Cook
keywords: Angiotensin type 1 receptor; angiotensins; cell-penetrating peptides